Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform

3 years ago

Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust…

Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101

3 years ago

CLEVELAND, June 09, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received feedback from the…

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

3 years ago

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICMLLAUSANNE,…

Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference

3 years ago

SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel…

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023

3 years ago

LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled…

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

3 years ago

Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertinPatients…

Finch Announces Reverse Stock Split of Common Stock

3 years ago

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a…

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

3 years ago

Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60…

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

3 years ago

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM;…